Opthea to Participate in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference, August 15, 2024
Opthea (ASX/NASDAQ: OPT), a clinical-stage biopharmaceutical company focused on developing therapies for retinal diseases, has announced its participation in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference on August 15, 2024. The company's management will present and engage in one-on-one investor meetings during the event.
Key details of the virtual conference include:
- Presentation available on August 15, 2024, at 7:00 am ET
- Presenter: Frederic Guerard, PharmD, CEO of Opthea
- Webcast accessible via a provided link and on Opthea's website
This participation highlights Opthea's ongoing efforts to engage with investors and showcase its progress in developing novel therapies for retinal diseases, particularly wet age-related macular degeneration (wet AMD).
Opthea (ASX/NASDAQ: OPT), una società biopharmaceutica in fase clinica focalizzata nello sviluppo di terapie per le malattie retiniche, ha annunciato la sua partecipazione alla 4ª Conferenza Virtuale Annuale di Oculistica H.C. Wainwright, che si terrà il 15 agosto 2024. Il management dell'azienda presenterà e parteciperà a incontri individuali con gli investitori durante l'evento.
Dettagli chiave della conferenza virtuale includono:
- Presentazione disponibile il 15 agosto 2024, alle 7:00 ET
- Relatore: Frederic Guerard, PharmD, CEO di Opthea
- Webcast accessibile tramite un link fornito e sul sito web di Opthea
Questa partecipazione sottolinea gli sforzi in corso di Opthea per interagire con gli investitori e mostrare i progressi nello sviluppo di terapie innovative per le malattie retiniche, in particolare la degenerazione maculare legata all'età neovascolare (wet AMD).
Opthea (ASX/NASDAQ: OPT), una compañía biofarmacéutica en etapa clínica enfocada en el desarrollo de terapias para enfermedades retinales, ha anunciado su participación en la 4ª Conferencia Virtual Anual de Oftalmología H.C. Wainwright que se llevará a cabo el 15 de agosto de 2024. La dirección de la compañía presentará y participará en reuniones individuales con inversores durante el evento.
Detalles clave de la conferencia virtual incluyen:
- Presentación disponible el 15 de agosto de 2024, a las 7:00 am ET
- Presentador: Frederic Guerard, PharmD, CEO de Opthea
- Webcast accesible a través de un enlace proporcionado y en el sitio web de Opthea
Esta participación destaca los esfuerzos continuos de Opthea para interactuar con los inversores y mostrar su progreso en el desarrollo de nuevas terapias para enfermedades retinales, particularmente la degeneración macular relacionada con la edad húmeda (wet AMD).
Opthea (ASX/NASDAQ: OPT)는 망막 질환 치료제를 개발하는 임상 단계의 생물 의약품 회사로, H.C. Wainwright 제4회 연례 안과학 가상 컨퍼런스에 참여한다고 발표했습니다. 컨퍼런스는 2024년 8월 15일에 열리며, 회사의 경영진이 발표하고 투자자와의 개별 미팅에 참여할 예정입니다.
가상 컨퍼런스의 주요 내용은 다음과 같습니다:
- 2024년 8월 15일 오전 7:00 ET에 발표 예정
- 발표자: Frederic Guerard, PharmD, Opthea CEO
- 제공된 링크 및 Opthea 웹사이트를 통해 웹캐스트 접근 가능
이번 참여는 Opthea가 투자자와의 소통을 지속하고, 망막 질환, 특히 습형 노인성 황반변성(wet AMD)에 대한 혁신 치료제 개발의 진전을 보여주기 위한 노력을 강조합니다.
Opthea (ASX/NASDAQ: OPT), une entreprise biopharmaceutique en phase clinique axée sur le développement de thérapies pour les maladies rétiniennes, a annoncé sa participation à la 4ème Conférence Virtuelle Annuelle d'Ophthalmologie H.C. Wainwright, qui se tiendra le 15 août 2024. La direction de l'entreprise présentera et participera à des réunions individuelles avec les investisseurs pendant l'événement.
Détails clés de la conférence virtuelle incluent :
- Présentation disponible le 15 août 2024, à 7h00 ET
- Présentateur : Frederic Guerard, PharmD, PDG d'Opthea
- Webinaire accessible via un lien fourni et sur le site web d'Opthea
Cette participation met en évidence les efforts continus d'Opthea pour interagir avec les investisseurs et montrer ses progrès dans le développement de nouvelles thérapies pour les maladies rétiniennes, notamment la dégénérescence maculaire liée à l'âge humide (wet AMD).
Opthea (ASX/NASDAQ: OPT), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf die Entwicklung von Therapien für Netzhauterkrankungen konzentriert, hat seine Teilnahme an der 4. jährlichen virtuellen Augenheilkunde-Konferenz von H.C. Wainwright am 15. August 2024 bekannt gegeben. Das Management des Unternehmens wird während der Veranstaltung präsentieren und an Einzelgesprächen mit Investoren teilnehmen.
Wichtige Details zur virtuellen Konferenz sind:
- Präsentation verfügbar am 15. August 2024, um 7:00 Uhr ET
- Präsentierender: Frederic Guerard, PharmD, CEO von Opthea
- Webcast zugänglich über einen bereitgestellten Link und auf der Website von Opthea
Diese Teilnahme hebt die fortwährenden Bemühungen von Opthea hervor, mit Investoren in Kontakt zu treten und die Fortschritte bei der Entwicklung neuartiger Therapien für Netzhauterkrankungen, insbesondere der feuchten altersbedingten Makuladegeneration (wet AMD), zu präsentieren.
- None.
- None.
MELBOURNE, Australia and PRINCETON, N.J., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ: OPT, “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD), today announced that management will present at the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference and participate in one-on-one investor meetings on August 15, 2024.
Virtual Conference Details:
Presentation: Available on Thursday, August 15, 2024, 7:00 am ET
Presenter: Frederic Guerard, PharmD, CEO Opthea
The webcast will be accessible both via the link: https://journey.ct.events/view/bc8c5e95-651e-4824-bee8-923a1a7479fa and on the “Events & Presentations” section of Opthea’s website at http://ir.opthea.com/.
About Opthea
Opthea (ASX/NASDAQ:OPT) is a biopharmaceutical company developing novel therapies to address the unmet need in the treatment of highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME).
Opthea’s lead product candidate, sozinibercept, is being evaluated in two fully enrolled pivotal Phase 3 clinical trials (COAST, NCT04757636, and ShORe, NCT04757610) for use in combination with standard-of-care anti-VEGF-A monotherapies to improve overall efficacy and deliver superior vision gains compared to standard-of-care anti-VEGF-A agents.
To learn more, visit our website at www.opthea.com and follow us on X and LinkedIn.
Authorized for release to ASX by Frederic Guerard, CEO
Investor Inquiries
PJ Kelleher
LifeSci Advisors, LLC
Email: pkelleher@lifesciadvisors.com
Phone: 617-430-7579
Media Inquiries
Silvana Guerci-Lena
NorthStream Global Partners
Email: silvana@nsgpllc.com
Join our email database to receive program updates:
Tel: +61 (0) 3 9826 0399, Email: info@opthea.com Web: www.opthea.com
Source: Opthea Limited
FAQ
When is Opthea (OPT) presenting at the H.C. Wainwright Ophthalmology Virtual Conference?
Who will be presenting for Opthea (OPT) at the virtual conference?
How can investors access Opthea's (OPT) presentation at the virtual conference?
What is the main focus of Opthea's (OPT) clinical research?
